Table 2.

The most common grade ≥ 3 TRAEs of enfortumab vedotin

TRAEs	EV monotherapy	EV+Pb	EV+SG
	Grade ≥ 3	Grade ≥ 3	Grade ≥ 3
Maculopapular rash	+ +  +	+ +  +
Hyperglycemia	+ +  +	+
Neutropenia	+ +  + +  +	+ +	+
Peripheral sensory neuropathy	+ +	+ +
Diarrhea	+	+	+
Anemia	+ +  +	+	+
Fatigue	+ +  +	+ +  +	+
Increased lipase	+	+
Decreased appetite	+
Myelosuppression	+
Infection	+		+
Renal impairment	+
Hypertension	+

The data of TRAEs are based on the clinical trials listed in Table 1. Statistics were conducted on the basis of the most common TRAEs observed in each clinical trial. “ + ” represents one occurrence in the enumeration of the most common TRAEs in the corresponding clinical trial regimens